UPDATE 3-Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.